Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 5 for:    Longeveron
Previous Study | Return to List | Next Study

Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03169231
Recruitment Status : Recruiting
First Posted : May 30, 2017
Last Update Posted : November 11, 2019
Sponsor:
Information provided by (Responsible Party):
Longeveron LLC

Tracking Information
First Submitted Date  ICMJE May 24, 2017
First Posted Date  ICMJE May 30, 2017
Last Update Posted Date November 11, 2019
Actual Study Start Date  ICMJE July 6, 2017
Estimated Primary Completion Date June 30, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 25, 2017)
Change from baseline in 6 Minute Walk Test (6MWT) compared to placebo [ Time Frame: Baseline and 180 days post-infusion ]
Change from baseline in 6MWT compared to placebo at 180 days post-infusion
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03169231 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: November 7, 2019)
  • Change in patient reported outcome of overall physical function capacity using the PROMIS-Physical Function-Short Form 20a compared to placebo [ Time Frame: 180 days post-infusion ]
    Change from baseline in physical function will be measured to assess Patient-Reported Outcome Measurement compared to placebo at 180 days post infusion.
  • Change in TNF-alpha compared to placebo [ Time Frame: 180 days post-infusion ]
    Change in serum TNF-alpha compared to placebo
Original Secondary Outcome Measures  ICMJE
 (submitted: May 25, 2017)
  • Change in patient reported outcome of overall physical function capacity using the PROMIS-Physical Function-Short Form 20a compared to placebo [ Time Frame: 180 days post-infusion ]
    Change from baseline in physical function will be measured to assess Patient-Reported Outcome Measurement compared to placebo at 180 days post infusion.
  • Change in TNF-a compared to placebo [ Time Frame: 180 days post-infusion ]
    Change in serum TNF-a compared to placebo
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty
Official Title  ICMJE A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogenic Human Mesenchymal Stem Cells Infusion in Patients With Aging Frailty
Brief Summary This is a randomized, placebo-controlled, double-blind, parallel arm, multi-center Phase 2b study.
Detailed Description The objectives of this study are to assess safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) compared to placebo on 1) functional mobility and exercise tolerance, 2) patient-reported physical function, and 3) the inflammatory cytokine biomarker tumor necrosis factor (TNF-alpha).
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Aging Frailty
Intervention  ICMJE
  • Biological: Longeveron Mesenchymal Stem Cells (LMSCs)
    Intravenously delivered
  • Other: Placebo
    Intravenously delivered
Study Arms  ICMJE
  • Experimental: Study Group A
    Single peripheral IV infusion of 25 million Longeveron Mesenchymal Stem Cells (LMSCs)
    Intervention: Biological: Longeveron Mesenchymal Stem Cells (LMSCs)
  • Experimental: Study Group B
    Single peripheral IV infusion of 50 million Longeveron Mesenchymal Stem Cells (LMSCs)
    Intervention: Biological: Longeveron Mesenchymal Stem Cells (LMSCs)
  • Experimental: Study Group C
    Single peripheral IV infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs)
    Intervention: Biological: Longeveron Mesenchymal Stem Cells (LMSCs)
  • Experimental: Study Group D
    Single peripheral IV infusion of 200 million Longeveron Mesenchymal Stem Cells (LMSCs)
    Intervention: Biological: Longeveron Mesenchymal Stem Cells (LMSCs)
  • Placebo Comparator: Study Group E
    Single peripheral IV infusion of placebo.
    Intervention: Other: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: December 14, 2018)
150
Original Estimated Enrollment  ICMJE
 (submitted: May 25, 2017)
120
Estimated Study Completion Date  ICMJE September 28, 2020
Estimated Primary Completion Date June 30, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Be willing and able to provide written informed consent and comply with all procedures required by the Protocol.
  2. Be >70 and < 85 years of age at the time of signing the Informed Consent Form.
  3. Have a Canadian Study on Health and Aging (CSHA) Clinical Frailty Scale score of 5 "mildly frail" or 6 "moderately frail".
  4. Have a 6 minute walk distance of > 200m and < 400 m. Distances of two 6MWTs are to be within 15% of each other.
  5. Have a serum TNF-alpha level > 2.5 pg/mL

Exclusion Criteria:

  1. Be unwilling or unable to perform any of the assessments required by the protocol.
  2. Have a diagnosis of any disabling neurologic disorder, including, but not limited to, Parkinson's disease, Amyotrophic Lateral Sclerosis, multiple sclerosis, cerebrovascular accident with residual deficits (e.g., muscle weakness or gait disorder), or diagnosis of dementia.
  3. Have a score of 24 or lower on the Mini Mental State Examination (MMSE)
  4. Have poorly controlled blood glucose levels (HbA1c >8.0%).
  5. Have a clinical history of malignancy within 2.5 years (i.e., subjects with prior malignancy must be cancer free for 2.5 years) except curatively-treated basal cell carcinoma, melanoma in situ or cervical carcinoma.
  6. Have any condition that in the opinion of the Principal Investigator limits lifespan to < 1 year.
  7. Have autoimmune disease (e.g. rheumatoid arthritis, systemic lupus erythematosus).
  8. Be using chronic immunosuppressant therapy such as high-dose corticosteroids or TNF-alpha antagonists (prednisone use at doses of < 5 mg daily is allowed).
  9. Test positive for hepatitis B virus

    a. If the subject tests positive for anti-hepatitis B core antigen (HBc) or anti-HBs, they must be currently receiving treatment for Hepatitis B prior to infusion and remain on treatment throughout the study.

  10. Test positive for verimic Hepatitis C virus, HIV1/2, or syphilis
  11. Have a resting blood oxygen saturation of <93% (measured by pulse oximetry).
  12. Known or suspected alcohol or drug abuse within three years preceding Screening
  13. Have a known hypersensitivity to dimethyl sulfoxide (DMSO).
  14. Be an organ transplant recipient (other than transplantation for corneal, bone, skin, ligament, or tendon).
  15. Be actively listed (or expected future listing) for transplant of any organ (other than corneal transplant).
  16. Have any clinically important abnormal screening laboratory values, including, but not limited to:

    1. Hemoglobin <10.0 g/dL,
    2. White blood cell <2,500/ul, or platelet count <100,000/ul
    3. Liver dysfunction evidenced by enzymes (AST and ALT) > 3 times the upper limit of normal (ULN)
    4. Coagulopathy (INR>1.3) not due to a reversible cause (e.g. warfarin and/or Factor Xa inhibitors).
  17. Uncontrolled hypertension (resting systolic blood pressure >180 mm Hg or diastolic blood pressure of > 110 mm Hg at Screening)
  18. Have unstable angina pectoris, uncontrolled or severe peripheral artery disease within the previous 3 months.
  19. Have congestive heart failure defined by NYHS (New York Heart Association) Class III or IV, or an ejection fraction of <25%.
  20. Have a coronary artery bypass surgery, angioplasty, or peripheral vascular disease revasculation or a myocardial infarction within previous 3 months.
  21. Have severe pulmonary dysfunction: acute exacerbation of chronic obstructive lung disease stage III or IV (Gold classification), and/or PaO2 levels <60 mmHg.
  22. Have a partial ileal gastric bypass, or other significant intestinal malabsorption.
  23. Have advanced liver or renal disease
  24. Have cognitive or language barriers that prohibit obtaining informed consent or any study elements.
  25. Be currently hospitalized, or living in an assisted living facility or a long-term care facility.
  26. Be currently participating (or participated within the previous 30 days of consent) in an investigational therapeutic or device trial.
  27. Have a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 70 Years to 85 Years   (Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Anthony Oliva, PhD 305-909-0840 aoliva@longeveron.com
Contact: Geoff Green 305-909-0837 ggreen@longeveron.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03169231
Other Study ID Numbers  ICMJE 001-03
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Longeveron LLC
Study Sponsor  ICMJE Longeveron LLC
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Longeveron LLC
Verification Date November 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP